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Background: Percutaneous treatment of coronary bifurcation lesions remains
hampered by suboptimal results, mainly in the side branch (SB), even with the use of
drug-eluting stents (DES). Drug-eluting balloons (DEB) could provide an attractive
alternative to treat bifurcations in combination with a provisional T-stenting technique
in order to minimize SB restenosis. We compared angiographic and clinical outcomes
of a provisional T-stenting technique with the first generation DIOR DEB plus bare
metal stent (BMS) versus BMS versus paclitaxel DES.
Methods: In this randomized, international multicenter, single-blinded 3-arm study,
117 patients with coronary bifurcation lesions underwent treatment with: A) DEB in
both main branch (MB) and SB and BMS in MB; B) BMS in MB and regular balloon
angioplasty in SB; or C) paclitaxel DES in MB and regular balloon in SB. All patients
underwent provisional T-stenting with an identical stent platform in the MB. Paclitaxel
was the drug for elution in groups A and C. This abstract presents the 18-month major
adverse cardiac events (MACE: death, myocardial infarction, target vessel
revascularization (TLR)) and 6-month angiographic results.
Results: In-hospital 8 MACE were reported, all were peri-procedural myocardial
infarctions (MI); 3 (7.5%), 2 (5.4%), and 3 (7.5%) in groups A, B, and C respectively.
Between discharge and 18-month follow-up results were: 1 (2.5%) cardiac death in
group A due to a nontarget vessel related MI. Furthermore, 1 (2.5%) MI due to a stent
thrombosis with consecutively a TLR was reported in group C. Total TLR rate at 18-
month was 8 (20%), 10 (27%), and 6 (15%) in groups A, B, and C respectively. The
cumulative MACE rate at 18-month was 22.5%, 29.7%, and 17.5% (p=0.47), and the
6-month angiographic binary restenosis rates per bifurcation were 24.2%, 28.6%, and
15% in groups A, B, and C respectively.
Conclusion: Pre-treatment of both MB and SB with the first generation DIOR DEB
failed to show 6-month angiographic and 18-month clinical superiority over BMS.
Moreover DES showed superior angiographic results than DEB and BMS.
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Background: The aim of the present study was to evaluate the temporal arterial
distribution of a novel nano particle sirolimus (nSRL) delivered locally using an
angioplasty balloon catheter in a rabbit ilio-femoral artery model.
Methods: The fluorescent dye 5-DTAF (Molecular Probes) was used to label nSRL
where 180 μg of drug was then spray-coated onto 3 x 15 mm balloon catheters (Magic
Touch, Concept Medical Inc., Twinsburg, OH). Bilateral ilio-femoral rabbit arteries
pre-injured with a 3F Fogarty catheter were treated with nSRL by 60 seconds inflation
of the balloon catheter at nominal pressure and harvested at 1, 24 hours and 3, 7 days
and assessed using laser confocal scanning microscopy.
Results: Confocal examination showed DTAF-nSRL as a solid to diffuse bright green
signal admixed with dark non-fluorescent areas (Fig. 1A). For arteries examined en
face, DTAF-signal was viewed as solid to more diffuse weaker fluorescence not to
exceed an estimated 25% to 35% of the luminal surface at 1 and 24-hours. At 3- and
7-days, the distribution of signal was markedly less. Histologic cross-sections examined
at 1 hr post-treatment showed a strong accumulation of DTAF-nSRL localized to the
IEL surface not exceeding 70% of the vessel circumference (Fig. 1B). By 24 and 72
hours however, the DTAF label was observed as a strong to faint punctate fluorescence
associated with the IEL and upper medial layer (Fig. 1C). At 7-days, the pattern of
DTAF was identified as a moderate to weak punctate fluorescence widely distributed
throughout the medial wall with rare particulate in the adventitia.
Figure 1. Representative confocal images.
Conclusion: The present study for the first time provides a visual assessment of the
distribution of a novel nano carrier sirolimus when delivered locally to the arterial wall
in vivo using a balloon catheter.
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Background: Previous pathologic studies in 1st-generation drug-eluting stents (1st-
gen DES; sirolimus- [SES] and paclitaxel- [PES]) have demonstrated that delayed
arterial healing is accompanied by poor endothelialization as the primary substrate
underlying late stent thrombosis (LST). Several clinical studies have reported that 2nd-
generation everolimus-eluting stent (EES) shows a lower incidence of LST than 1st-gen
DES. Little is known about the pathologic findings of EES in human coronary arteries.
Methods: From our stent registry, a total of 111 autopsy cases to include 155 DES
lesions (1st-gen DES=136 [61 SES, 75 PES] and EES=19) with duration of implant
>30 days and ≤2 years were examined. Histomorphometry was performed on EES vs.
1st-gen DES where endothelial strut coverage, fibrin deposition, and inflammatory
response were assessed.
Results: Age, sex, risk factors, and duration of implant (1st-gen DES=211 [91-383]
vs. EES=180 [151-360] days, p=0.64) were similar between 2 groups. LST was more
frequent in 1st-gen DES than in EES (25.7% vs. 5.3%, p=0.04). Only 1 lesion with
LST in EES was a device implanted over an underlying PES. The results of
histomorphometry are shown in Table. The percent of uncovered struts was
significantly lower in EES, while mean neointimal thickness did not differ between
the groups. Moreover, inflammation and fibrin deposition were significantly less in
EES as compared to 1st-gen DES.
Conclusion: EES shows a lower incidence of LST and substantially less uncovered
struts with similar neointimal thickness, less inflammation, and less fibrin deposition
as compared to 1st-gen DES in humans. These findings are consistent with greater
clinical safety of EES.
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Background: The present study sought to evaluate the safety and effectiveness of
Excel in acute myocardial infarction with 6-month dual antiplatelet therapy in daily
practice.
Methods: Since November 10, 2006, a policy of routine Excel stents implantation has
been instituted in 59 centers from 4 countries. During 6 months of enrollment, 760
patients with acute myocardial infarction underwent percutaneous recanalization and
Excel stents implantation. Six-month angiographic follow-up was scheduled per
protocol.
www.JACC.TCTAbstracts2011
B6 JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/ORAL/Drug-Eluting Stents I
O
R
A
L
S
